Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Preferred Stock Liabilities (2021 - 2023)

Elicio Therapeutics filings provide 3 years of Preferred Stock Liabilities readings, the most recent being $111.1 million for Q1 2023.

  • On a quarterly basis, Preferred Stock Liabilities rose 57.67% to $111.1 million in Q1 2023 year-over-year; TTM through Mar 2023 was $111.1 million, a 57.67% increase, with the full-year FY2022 number at $111.1 million, up 57.67% from a year prior.
  • Preferred Stock Liabilities hit $111.1 million in Q1 2023 for Elicio Therapeutics, roughly flat from $111.1 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $111.1 million in Q4 2022 to a low of $70.4 million in Q4 2021.
  • Median Preferred Stock Liabilities over the past 3 years was $76.0 million (2022), compared with a mean of $85.8 million.
  • The widest YoY moves for Preferred Stock Liabilities: up 57.67% in 2022, down 57.67% in 2022.
  • Elicio Therapeutics' Preferred Stock Liabilities stood at $70.4 million in 2021, then surged by 57.67% to $111.1 million in 2022, then changed by 0.0% to $111.1 million in 2023.
  • The last three reported values for Preferred Stock Liabilities were $111.1 million (Q1 2023), $111.1 million (Q4 2022), and $80.4 million (Q3 2022) per Business Quant data.